Current classifications of OMD assign one state per patient. But within the same patient, lesions respond, persist, and progress on divergent paths.
We propose metastatic trajectories – a lesion-level framework to guide local + systemic therapy in metastatic NSCLC.
📄 @JCO_ASCO
New in @JCO_ASCO from @IyengarPuneeth and colleagues: proposing "metastatic trajectories," a lesion-level framework for metastatic NSCLC, recognizing that different metastases within the same patient can evolve along divergent biological paths.
Read more: https://t.co/8xhlJKx8YH
Just published in the #GreenJournal: Leveraging the potential of prospective registries for radiation oncology research: 5-year experience from the
@EORTC-ESTRO #radiotherapy infrastructure for Europe (E2-RADIatE) project
👉 Read the abstract: https://t.co/fReo0jxxpC
The primary is the source of first progression in >50% of cases of #lungcancer patients, and TRACERx showed us that in 32% of NSCLC the primary polyclonally seeds metastases. In our @IASLC consensus, now in JTO https://t.co/9LzfFi4ICc, makes the case for eradicating it with #radiotherapy. The EGFRm phase III data are the most compelling OS 34.4 vs 26.2 months with TKI+RT. There are still unresolved questions in the non-AGA population. We are opening the phase III PRIME-LUNG trial https://t.co/4J4JsgWu31 @TROGfightcancer@TOGAANZ to answer this question! #radonc
New data on #oligometastatic#ProstateCancer from #ESTRO26:
1️⃣EXTEND: ctDNA= a powerful prognostic tool, though MDT benefits patients regardless of ctDNA status
2️⃣OLIGOPELVIS-2: Salvage nodal RT to para-aortic nodes has manageable long-term side effects.
👉https://t.co/1kr7sW0i0s
Detecting lung cancer 5 years before it happens, in @CellCellPress courtesy of the @CharlesSwanton group.
Astonishing translational work !
https://t.co/EvUmIGVLgs
What does chemo add to immunotherapy in pts w/ PD-L1-high NSCLC?
In our meta-analysis of 24 trials w/ reconstructed individual patient data, we observed a meaningful improvement in both median PFS (11.3 vs 6.8 months, HR 0.74) and OS (29.2 vs 19.8 months, HR 0.67) w/ chemo-ICI.
What a happy coincidence!
While presenting intracranial efficacy data from DeLLphi-304 in #ASCO26, #Tarlatamab was officially approved in EU!!
✅ In ITT: CNS mPFS NR vs 7.8 m, HR=0.54
✅ In BM per mRANO: CNS mPFS 6.5 vs 4.2m, HR=0.4
✅ mOS=13.9 vs 6.8, HR=0.51, independent of baseline BM!
A new SoC, hope that all #SCLC patients will soon have access!!
#some #LCSM @OncoAlert@OncBrothers@OncLive@PortalOnconews@SclcSMASHERS@myESMO@ASCO@IASCL@PeerView
Negative phase III trial of concurrent thoracic RT in ES-SCLC receiving chemoimmunotherapy.
TRT was initiated early (between cycles 2 and 3), and failed to improve outcomes:
• Median OS 10.0 vs 11.8 months
• No improvement in response rate
• More adverse events and treatment-related deaths While disappointing, these results should not be extrapolated to all consolidative TRT strategies. One key difference from SAKK 15/19 is timing: RT here was delivered concurrently with ongoing chemoimmunotherapy, whereas SAKK 15/19 administers TRT after completion of induction treatment and no major toxicity was detected
Perhaps the lesson is not that thoracic RT has no role, but that timing matters. https://t.co/njhvrV4590
#ASCO26 #SCLC #LungCancer #Radiotherapy
ASCO2026: Asymptomatic brain met EGFR/ALK NSCLC any benefit upfront cranial RT on this Randomized trial?
- Upfront RT ↑↑ brain control, no benefit PFS, OS
- Selection criteria high risk (e.g. larger size) for upfront RT is key
https://t.co/1CM31nbxeL
🫁 Metastatic trajectories in NSCLC: redefining local + systemic therapy through disease evolution! @JCO_ASCO
https://t.co/XcpEhaGHML
▪️ Genomics + ctDNA + radiomics + functional imaging
▪️ Defines progression by pace, pattern, organotropism & resistance mechanisms
▪️ Adaptive strategies: escalate, switch, consolidate or locally ablate
▪️ Could reshape biomarker-driven platform trials in mNSCLC
Not all metastases follow the same road…some take very different “trajectories” 🚦
@OncoAlert@OncoReporte@myESMO@_SEOM@LungCancerRx@Lung_Cancers@gecp_org
What a beautiful message at the end of @Mat_Guc presidency at #ESTRO26 passing the torch to @BarbaraJereczek! See you at #ESTRO27 in Milano, 21-25th of May 2027.
🎥 Out of #ESTRO26: Can a simple blood test change the definition of oligo metastases? 🩸
🧬 Researchers found that tracking circulating tumour DNA (ctDNA) could change how we manage #oligometastaticcancer 👇@AlexSherryMD
The OLIGOMA trial results are out! Breast #SBRT shows promising outcomes with stable patient quality of life.
Dr David Krug 🇩🇪 breaks down:
💡 Motivation for this breast cancer SBRT approach 🎯 Patient tolerance
🚀 Next steps
🎥 Watch 👇
#ESTRO26#RadOnc#BreastCancer
Congratulations @NAndratschke and the whole team - presenting @EORTC@ESTRO_RT E2-Radiate ReCare cohort to assess adequacy of patient selection #ESTRO26
Network and cooperation made the difference in science 🙏🏼💪🏼
#OncoAlert@OncoAlert
Kicking off the #Oligometastatic disease channel with an excellent debate on prostate irradiation in metastatic hormone-sensitive prostate cancer! #ESTRO26!